Aviceda Announces 3 Presentations about AVD-104, its Lead Gl

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private biotech company focused on developing the next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced their upcoming oral and poster...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Irvine , California , United States , Tareks Hassan , Michael Tolentino , Anitha Krishnan , Diyan Patel , Baruch Kuppermann , Association For Research , University Of California , Department Of Ophthalmology School Medicine , Aviceda Therapeutics , New Orleans , Chief Development Officer , Chief Technology Officer , Steinert Endowed Professor , Ophthalmology School , Presentation Details , Complement Dysfunction , Sialic Acid Coated Nanoparticle , Poster Details , Self Recognition Pattern Receptors , Retina Immune Cells , Engineered Glycan Coated Nanoparticle , Novel Therapy , Retinal Inflammatory Macrophages , Sialic Acid Coated Nanoparticles ,